公开(公告)号：US12233127B2

公开(公告)日：2025-02-25

申请号：US17270115

申请日：2019-08-22

Applicant: Vanderbilt University

Inventor： James E. Crowe, Jr.

IPC: A61K39/42 ,  A61P31/16 ,  C07K16/10 ,  G01N33/569 ,  A61K39/00

Abstract: The present disclosure is directed to antibodies binding previously undefined epitopes on influenza A virus hemagglutinin and methods for use thereof.

公开(公告)号：US20250049879A1

公开(公告)日：2025-02-13

申请号：US18716764

申请日：2022-12-07

Applicant: PM GROUP COMPANY LIMITED

Inventor： Prayudh MAHAGITSIRI ,  Chalermchai MAHAGITSIRI ,  Ausana MAHAGITSIRI ,  Thomas JAKSCHITZ ,  Gökhan SENLI ,  Günther BONN

IPC: A61K36/77 ,  A61K31/192 ,  A61K31/197 ,  A61K31/357 ,  A61K31/366 ,  A61K31/375 ,  A61K31/7024 ,  A61P31/14 ,  A61P31/16

Abstract: The present invention relates to a composition comprising or corresponding to an extract obtained from Dimocarpus longan for use in the treatment and/or prevention of a disease caused by an enveloped virus, in particular caused by coronaviruses such as SARS-CoV, MERS-CoV and SARS-CoV-2 or influenza viruses such as influenza A and influenza B and/or at least one symptom thereof.

公开(公告)号：US12220454B2

公开(公告)日：2025-02-11

申请号：US17199972

申请日：2021-03-12

Applicant: Purdue Research Foundation

Inventor： Suresh Kumar Mittal

IPC: A61K39/145 ,  A61P31/16 ,  A61P37/04 ,  A61K39/00

Abstract: Disclosed herein a unique cell line system to generate a novel bovine adenovirus vector that provides more gene insertion capabilities and better immunogenicity for inserted antigens. The unique cell line is used for generating and growing of the new adenovirus vectors for gene delivery or recombinant vaccine production.

公开(公告)号：US20250000972A1

公开(公告)日：2025-01-02

申请号：US18374118

申请日：2023-09-28

Applicant: ADVAGENE BIOPHARMA CO., LTD.

Inventor： YU-SHEN HSU ,  SSU-WEI KANG ,  MINGI CHANG

IPC: A61K39/39 ,  A61K39/145 ,  A61K39/215 ,  A61P31/14 ,  A61P31/16 ,  A61P37/04

Abstract: The present disclosure provides a method for vaccinating a subject against a mucosal virus infection, comprising administering to the subject an immunologically effective amount of an intranasal booster, wherein the intranasal booster comprises detoxified Escherichia coli labile toxin (LT) and an antigen from the mucosal virus, and wherein the subject has been previously primed. An intranasal vaccine composition comprising an immunologically effective amount of a mucosal virus antigen adjuvanted with a detoxified Escherichia coli labile toxin (LT) is also provided.

公开(公告)号：US20250000877A1

公开(公告)日：2025-01-02

申请号：US18708357

申请日：2022-10-28

Applicant: SHAPERON INC. ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Seung Yong SEONG

IPC: A61K31/575 ,  A61P31/16

Abstract: The present invention relates to a composition for preventing or treating virus infection diseases containing taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient. Specifically, inflammatory cells and inflammatory cytokines were found to decrease in the lungs of an influenza virus-infected animal model to which taurodeoxycholic acid or a pharmaceutically acceptable salt thereof was administered as an inflammasome inhibitor, and thus the inflammasome inhibitor containing taurodeoxycholic acid or a pharmaceutically acceptable salt thereof can be used as an active ingredient in the composition for preventing or treating virus infection diseases.

公开(公告)号：US12180267B2

公开(公告)日：2024-12-31

申请号：US18335874

申请日：2023-06-15

Applicant: The University of Chicago

Inventor： Patrick Wilson ,  Yaoqing Chen ,  Haley L. Dugan

IPC: C07K16/10 ,  A61K39/42 ,  A61K45/06 ,  A61P31/16 ,  A61K39/00

Abstract: Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.

公开(公告)号：US20240425852A1

公开(公告)日：2024-12-26

申请号：US18774194

申请日：2024-07-16

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Jeffrey S. Glenn ,  Rachel Hagey Saluti ,  Edward A. Pham

IPC: C12N15/11 ,  A61P31/16

Abstract: Methods of inhibiting influenza A virus in a sample are provided. Aspects of the methods include contacting a sample comprising viral RNA (vRNA) having a PSL2 motif with an effective amount of an agent that specifically binds the PSL2 motif to inhibit the influenza A virus. Also provided are methods of treating or preventing influenza A virus infection in a subject. Also provided are methods for screening a candidate agent for the ability to inhibit influenza A virus in a cell, the method comprising: contacting a sample with a candidate agent; and determining whether the candidate agent specifically binds to the PSL2 motif of vRNA. Also provided are compounds and pharmaceutical compositions comprising an oligonucleotide sequence complementary to a PB2 vRNA region that find use in the subject methods.

公开(公告)号：US12161646B2

公开(公告)日：2024-12-10

申请号：US17044079

申请日：2019-04-11

Applicant: JIAXING ANDICON BIOTECH CO., LTD.

Inventor： Xiaoyun Zhu ,  Weiping Jiang

IPC: A61K31/5383 ,  A61K31/13 ,  A61K31/196 ,  A61K31/351 ,  A61K31/426 ,  A61K31/4965 ,  A61K31/506 ,  A61K31/53 ,  A61K39/395 ,  A61K45/06 ,  A61P31/16 ,  C07D471/14 ,  C07D491/22 ,  C07D498/14

Abstract: The present invention discloses a group of polycyclic carbamoylpyridone derivatives, pharmaceutical compositions, and a use thereof. The structure of the polycyclic carbamoylpyridone derivatives of the present invention is represented by formula (VII). The polycyclic carbamoylpyridone derivative of the present invention functions as an inhibitor of influenza 5′cap-like structure (CAP)-dependent endonuclease activity and can be used to treat a cold caused by the influenza virus. The present invention also discloses a pharmaceutical composition to inhibit proliferation of the influenza virus.

公开(公告)号：US20240390293A1

公开(公告)日：2024-11-28

申请号：US18572676

申请日：2022-06-23

Applicant: UNIVERSITÉ LAVAL

Inventor： René MALTAIS ,  André MARETTE ,  Donald POIRIER ,  Jean-Yves SANCÉAU ,  Guy BOIVIN

IPC: A61K31/085 ,  A61K31/047 ,  A61K31/133 ,  A61K31/202 ,  A61K31/4453 ,  A61P31/16

Abstract: Derivatives of 10S, 17S-diHIDA (protectin DX, PDX) and medicinal uses thereof are disclosed. These derivatives are specialized pro-resolving mediators (SPRMs). In specific embodiments, said derivatives are used in to prevent or treat viral infections (including influenza and coronavirus infections), insulin resistance, diabetes, and inflammatory disorders.

公开(公告)号：US12139527B2

公开(公告)日：2024-11-12

申请号：US18335872

申请日：2023-06-15

Applicant: The University of Chicago

Inventor： Patrick Wilson ,  Yaoqing Chen ,  Haley L. Dugan

IPC: C07K16/10 ,  A61K39/42 ,  A61K45/06 ,  A61P31/16 ,  A61K39/00

Abstract: Provided herein are anti-neuraminidase agents useful for neutralization of influenza virus infection, and methods of use and manufacture thereof. In particular, compositions comprising anti-neuraminidase agents (e.g., antibodies) that are cross-reactive with multiple influenza strains are provided, as well as methods of treatment and prevention of influenza infection therewith.